Nogueiras-Álvarez Rita, García-Sáiz María Del Mar
Clinical Trials Unit, Bioaraba Health Research Institute, 01009 Vitoria-Gasteiz, Spain.
Clinical Pharmacology Service, Marqués de Valdecilla University Hospital, 39008 Santander, Spain.
Pharmacy (Basel). 2024 Jan 22;12(1):17. doi: 10.3390/pharmacy12010017.
Once a solid organ transplantation (SOT) has been performed, it is necessary to prescribe immunosuppressant medication to prevent graft rejection. This task has the peculiarity that many of these drugs do not have specific indications for transplant use in the technical data sheets. We performed a review of different immunosuppressive drugs' information available at European and American regulatory agencies in order to analyze the approved indications by the type of SOT. In our work, besides showing these differences between different indication approvals in different SOT modalities, we also attempted to reflect other differences under the approved indications according to age group, formulation type, geographical area, etc. Although consensus documents on the subject have been published, the access to immunosuppressants depends on each country's regulation and healthcare system, and off-label prescription is a reality that healthcare professionals need to be familiar with.
一旦进行了实体器官移植(SOT),就有必要开具免疫抑制药物以防止移植物排斥。这项任务的特殊之处在于,许多此类药物在技术数据表中没有移植用途的特定适应症。我们对欧美监管机构提供的不同免疫抑制药物信息进行了综述,以便按SOT类型分析批准的适应症。在我们的工作中,除了展示不同SOT模式下不同适应症批准之间的这些差异外,我们还试图反映批准适应症下根据年龄组、剂型、地理区域等的其他差异。尽管已经发表了关于该主题的共识文件,但免疫抑制剂的获取取决于每个国家的法规和医疗保健系统,而超说明书用药是医疗专业人员需要熟悉的现实情况。